Rishabh Jain, Medical Oncologist at AIIMS, shared a post on X:
“Predicting cardiomyopathy after breast cancer using routine clinical variables
We do not need new biomarkers or fancy imaging to predict cardiotoxicity. We need to use what we already have.
This JAMA Oncology study presents a validated, diagnosis-day model that estimates 10-year heart failure or cardiomyopathy (HF/CM) risk after early-stage breast cancer treatment.
- 26,044 women with local or regional breast cancer
- Age 18-79 years, treated 2008-2020
- Median follow-up 5.2 years
Built only on routine data
- Age
- Type of systemic therapy (anthracycline, ERBB2 therapy, non-anthracycline chemotherapy)
- Radiation laterality
- Hypertension, diabetes, obesity
- Smoking and prior cardiovascular disease
What it shows
- A 10-fold difference in long-term risk
- 10-year HF/CM incidence 1.7% in low-risk vs 19.4% in high-risk patients
- Strong discrimination with AUC 0.79 at 10 years
Why this changes practice
- Most survivors do not need blanket echocardiography
- Some clearly need closer surveillance
- This model helps us tell the difference at diagnosis Full paper in comment.”
More posts featuring Rishabh Jain on OncoDaily.